{"id":544434,"date":"2015-03-22T14:34:39","date_gmt":"2015-03-22T13:34:39","guid":{"rendered":"https:\/\/hpsitaly.healthcare\/?p=544434"},"modified":"2022-03-26T16:26:54","modified_gmt":"2022-03-26T15:26:54","slug":"gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch","status":"publish","type":"post","link":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/","title":{"rendered":"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch"},"content":{"rendered":"<p><strong>AboutMedicine Flash Anno III, N. 8, marzo 2015<\/strong><\/p>\n<p><strong>Valentina Svicher e Carlo Federico Perno, Universit\u00e0 degli Studi di Roma \u201cTor Vergata\u201d<\/strong><\/p>\n<p><strong>Indice<\/strong><\/p>\n<ul>\n<li>Introduzione<\/li>\n<li>Fattori che possono promuovere lo sviluppo di ceppi resistenti a lamivudina<\/li>\n<li>Uso di lamivudina nella profilassi della riattivazione di HBV indotta da immunosoppressione<\/li>\n<li>Implicazioni patogenetiche nello sviluppo di ceppi resistenti a lamivudina<\/li>\n<li>Conclusioni<\/li>\n<li>Schema riepilogativo dei fattori chiave associati a sviluppo di ceppi resistenti a lamivudina<\/li>\n<li>Bibliografia<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>AboutMedicine Flash Anno III, N. 8, marzo 2015 Valentina Svicher <a href=\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":64199,"featured_media":544962,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[997,989],"tags":[],"class_list":["post-544434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aboutmedicine-eng","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS\" \/>\n<meta property=\"og:description\" content=\"AboutMedicine Flash Anno III, N. 8, marzo 2015 Valentina Svicher [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\" \/>\n<meta property=\"og:site_name\" content=\"HPS\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-22T13:34:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-26T15:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png\" \/>\n\t<meta property=\"og:image:width\" content=\"589\" \/>\n\t<meta property=\"og:image:height\" content=\"845\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Eleonora Zaghis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eleonora Zaghis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\",\"url\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\",\"name\":\"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS\",\"isPartOf\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png\",\"datePublished\":\"2015-03-22T13:34:39+00:00\",\"dateModified\":\"2022-03-26T15:26:54+00:00\",\"author\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\"},\"breadcrumb\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage\",\"url\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png\",\"contentUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png\",\"width\":589,\"height\":845,\"caption\":\"Gestione del paziente trattato a lungo termine con lamivudina\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hpsitaly.healthcare\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\",\"url\":\"https:\/\/hpsitaly.healthcare\/\",\"name\":\"HPS\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hpsitaly.healthcare\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\",\"name\":\"Eleonora Zaghis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"caption\":\"Eleonora Zaghis\"},\"url\":\"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/","og_locale":"en_US","og_type":"article","og_title":"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS","og_description":"AboutMedicine Flash Anno III, N. 8, marzo 2015 Valentina Svicher [...]","og_url":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/","og_site_name":"HPS","article_published_time":"2015-03-22T13:34:39+00:00","article_modified_time":"2022-03-26T15:26:54+00:00","og_image":[{"width":589,"height":845,"url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png","type":"image\/png"}],"author":"Eleonora Zaghis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Eleonora Zaghis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/","url":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/","name":"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch - HPS","isPartOf":{"@id":"https:\/\/hpsitaly.healthcare\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage"},"image":{"@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage"},"thumbnailUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png","datePublished":"2015-03-22T13:34:39+00:00","dateModified":"2022-03-26T15:26:54+00:00","author":{"@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd"},"breadcrumb":{"@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#primaryimage","url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png","contentUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/03\/Gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina.png","width":589,"height":845,"caption":"Gestione del paziente trattato a lungo termine con lamivudina"},{"@type":"BreadcrumbList","@id":"https:\/\/hpsitaly.healthcare\/en\/uncategorized\/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hpsitaly.healthcare\/en\/"},{"@type":"ListItem","position":2,"name":"Gestione del paziente trattato a lungo termine con lamivudina: fattori correlati con l\u2019insorgenza di resistenza e implicazioni per il pro-active switch"}]},{"@type":"WebSite","@id":"https:\/\/hpsitaly.healthcare\/#website","url":"https:\/\/hpsitaly.healthcare\/","name":"HPS","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hpsitaly.healthcare\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd","name":"Eleonora Zaghis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","caption":"Eleonora Zaghis"},"url":"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/"}]}},"_links":{"self":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/users\/64199"}],"replies":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/comments?post=544434"}],"version-history":[{"count":3,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544434\/revisions"}],"predecessor-version":[{"id":545558,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544434\/revisions\/545558"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media\/544962"}],"wp:attachment":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media?parent=544434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/categories?post=544434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/tags?post=544434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}